GRAI-MATTER-LABS
14.9.2021 09:02:12 CEST | Business Wire | Press release
GrAI Matter Labs (GML), a pioneer of brain-inspired computing solutions, announced today that it has entered a partnership with ERM Automatismes (ERM), a French market leader for didactic solutions in technological and professional training for 30 years, to create a ROS2-based robotics education kit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005311/en/
The Life-Ready AI Kit for Education combines robotics with brain-inspired AI as the key ingredient for Industry 4.0. The kit is comprised of a robot arm with a 2D/3D camera for visual perception, and a GML GrAI VIP platform integrated with an ADLINK I-Pi SMARC module. The ERM curriculum includes modules for grasping, regression, classification and more. It was developed with teachers from the French academy, universities, and a community of AI specialists to offer a very practical and easy to use model for teachers and students.
GML and ERM will showcase the education kit at the SIDO Fair in Lyon starting on 22nd of September. This unique kit, using GML's “Life-Ready AI” chip, GrAI VIP will demonstrate a real-life application of classifying agricultural products on a conveyor belt.
“We are delighted to be collaborating with ERM to teach our new generation of engineers cutting edge AI technologies. The students will learn to apply energy efficient machine-learning algorithms in an industrial context and help to kickstart a Life-Ready AI ecosystem which helps to save time, money and vital natural resources for Industry 4.0,” said Christian Verbrugge, GML Europe - Senior Director Business Development.
Cyril Liotard, CEO of ERM, is excited about the partnership, saying “with GrAI Matter Labs, we are expanding our existing portfolio with Life-Ready AI technology. GML offers a one-of-a-kind brain-inspired computing architecture that has never been seen before in education; that is why we are thrilled to collaborate with GML, and academia to achieve this goal together.”
About GrAI Matter Labs
At GrAI Matter Labs we are in the business of Life-Ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. We deliver brain-inspired chips that behave like humans. AI that makes machines act and react in real-time. AI that optimizes energy and maximizes efficiency, saving time, money, and vital natural resources. GML is led by a team of visionary and seasoned engineers and is backed by leading investors, including iBionext, 360 Capital Partners, 3T Finance, and Celeste Management.
For more information, please visit www.graimatterlabs.ai .
About ERM Automatismes
ERM Automatismes, founded in 1990, is a French company that provides technical systems and services in education, robotics, Fab&Test, and energy; and has developed didactic solutions for technological training as well as robotic and mechatronic solutions for the food industry. ERM provides a wide range of manufacturing and testing solutions to meet the growing needs of industrial customers, schools, colleges, universities, and engineering schools, as well as local authorities, municipalities, departments, and regions.
For more information, please visit https://www.erm-automatismes.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005311/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom